Výsledky vyhledávání - "Janmaat, M. L."

Akademický článek

P854: HEXABODY‐CD38 INDUCES TROGOCYTOSIS AND EFFECTIVELY INDUCES COMPLEMENT‐MEDIATED TUMOR CELL LYSIS AFTER TREATMENT WITH DARATUMUMAB OR ISATUXIMAB IN VITRO.

Autor: Hiemstra, I. H., Santegoets, K., Janmaat, M. L., Ten Hagen, W., Van Dooremalen, S., De Goeij, B. E., Bosgra, S., Sasser, A. K., Breij, E. C.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p747-748, 2p

Zobrazit plný text záznamu

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways

Autor: Janmaat, M. L., Kruyt, F. A. E., Rodriguez, J. A., Giuseppe Giaccone

Publikováno v: Scopus-Elsevier
Clinical Cancer Research, 9(6), 2316-2326. AMER ASSOC CANCER RESEARCH

The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In this study, we examined the molecular mechanisms that underlie the antitumor effects of the anti-EGFR monoclonal antibody C225 (Cetuximab) and the sel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::eec914faf1442af91e400ca8140d9a6d
http://www.scopus.com/inward/record.url?eid=2-s2.0-0037499945&partnerID=MN8TOARS

Zobrazit plný text záznamu

Akademický článek

The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.

Autor: Janmaat ML; Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands., Giaccone G

Publikováno v: Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2003; Vol. 39 Suppl C, pp. 61-80.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání